NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,280.61 +79.34 (+0.46%) CRUDE OIL
82.89 +0.08 (+0.10%) GOLD FUTURES
2,332.20 -6.20 (-0.27%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,411.43 -2,017.91 (-3.78%)
Standard BioTools Inc. (FLB.F)
| Previous close | 2.3600 |
| Open | 2.2200 |
| Bid | 0.0000 x 50000 |
| Ask | 0.0000 x 50000 |
| Day's range | 2.2200 - 2.2200 |
| 52-week range | 1.3300 - 2.8000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 849.063M |
| Beta (5Y monthly) | 1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8800 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
Simply Wall St.Standard BioTools Inc. (NASDAQ:LAB): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Standard BioTools Inc.'s ( NASDAQ:LAB ) business as it appears the company...
GlobeNewswireStandard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
New advancements, including automation, aim to fast-forward spatial biologySOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the introduction of new solutions that add automation and flexibility to the Imaging Mass Cytometry™ workflow on the Hyperion XTi™ Imaging System. Spatial biology is vital to clinical and translational research, provi
- GlobeNewswire
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb for use of the SomaScan® Platform as a tool for clinical trials in multiple therapeutic areas through 2026. The SomaScan Platform is a high-throughput proteomics technology that presen
